Southwest Oncology Group: two decades of experience in non-small cell lung cancer.
Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.
Turrisi
Andrew T
AT
Department of Radiation Oncology, Karmanos Cancer Center, Wayne State University, 540 E. Canfield, 1212 Scott Hall, Detroit, MI 48201, USA. aturrisi@med.wayne.edu
Crowley
John
J
Albain
Kathy
K
Gaspar
Laurie
L
Gandara
David
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D011879:Radiotherapy Dosage